Back to top
more

Journey Medical (DERM)

(Delayed Data from NSDQ)

$7.75 USD

7.75
263,479

+0.26 (3.47%)

Updated Aug 21, 2026 04:00 PM ET

After-Market: $7.77 +0.02 (0.26%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (102 out of 247)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Compared to Estimates, Journey Medical (DERM) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Journey Medical (DERM) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Journey Medical Corporation (DERM) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Journey Medical (DERM) delivered earnings and revenue surprises of -12.50% and -0.39%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Guardian Pharmacy Services (GRDN) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Guardian Pharmacy (GRDN) delivered earnings and revenue surprises of +4.17% and +6.63%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

electroCore, Inc. (ECOR) Reports Q3 Loss, Beats Revenue Estimates

by Zacks Equity Research

electroCore (ECOR) delivered earnings and revenue surprises of -11.11% and +10.69%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

OmniAb, Inc. (OABI) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

OmniAb, Inc. (OABI) delivered earnings and revenue surprises of 0.00% and -62.97%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

New Strong Sell Stocks for September 4th

by Zacks Equity Research

DERM, HOPE and NXRT have been added to the Zacks Rank #5 (Strong Sell) List on September 4, 2025.

Zacks Equity Research

Journey Medical Corporation (DERM) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

Journey Medical (DERM) delivered earnings and revenue surprises of -128.57% and +1.11%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Ekta Bagri headshot

3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

by Ekta Bagri

Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.

Zacks Equity Research

Journey Medical Corporation (DERM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Journey Medical (DERM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Journey Medical Corporation (DERM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Journey Medical (DERM) delivered earnings and revenue surprises of 25% and 10.55%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?